Iris Device Management System FacilitatesRemote Management of
Masimo Point-of-care Devices Throughout the Hospital
IRVINE, Calif.--(BUSINESS WIRE)--Jan. 22, 2019--
Masimo (NASDAQ:
MASI) announced today the U.S. launch of Iris® Device
Management System (Iris DMS), an automation and connectivity solution
designed to streamline management of Masimo devices used throughout a
hospital system.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190122005192/en/
Masimo Iris® Device Management System (Photo: Business Wire)
Iris DMS is designed to address the challenges of maintaining many
patient monitors in a complex hospital environment. Iris DMS securely
connects over a hospital’s existing network to all connected Masimo
devices to provide an easy-to-use dashboard that allows Biomedical
Engineers and IT professionals to view detailed diagnostic information
about connected Masimo devices at a glance, without the need to
physically interact with each device. Iris DMS supports remote software
upgrades to ensure all devices stay up to date, easily and efficiently.
Patient profiles, policy files, and network settings can be distributed
to multiple devices in a single step, simplifying device management. In
addition, connected devices routinely “ping” Iris DMS, allowing users to
quickly identify any operational issues with any single Masimo device
using the intuitive display of near real-time connection status.
Joe Kiani, Founder and CEO of Masimo, said, “More and more clinicians
are recognizing the benefits of providing continuous Masimo patient
monitoring, not just during surgery or in the ICU, but in all
medical-surgical wards, especially for patients on opioids. Masimo
patient monitoring devices are more powerful and full-featured than
ever, but as a result their software is increasingly complex. Just as
with consumer tech devices, medical devices now undergo regular
iterative software updates as new innovations and features become
available – helping prolong their utility and augmenting their abilities
– and as security patches are issued. Iris DMS not only helps Biomedical
and IT professionals view detailed diagnostic information about
connected Masimo devices at a glance, but helps to simplify the process
of maintaining, updating, and standardizing these devices, helping
clinicians and hospitals stay focused on providing the best patient care
using the most up-to-date technology, not worrying about device
maintenance. Iris DMS is another great example of Masimo’s pursuit of
holistic care solutions that improve patient outcomes and reduce costs
across the continuum of care.”
@MasimoInnovates |
#Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™
in post-surgical wards, reduce rapid response activations and costs.3-5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 9 of the top 10
hospitals listed in the 2018-19 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States. The use of the trademark Patient SafetyNet is
under license from University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
-
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue
events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
-
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Iris® Device Management System. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo Iris Device Management
System, contribute to positive clinical outcomes and patient safety;
risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the “Risk Factors” section of our
most recent reports filed with the Securities and Exchange Commission
(“SEC”), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005192/en/
Source: Masimo
Media:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com